The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will have a significant impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years. Although physicians will welcome additional treatment options for this chronic disease as a result of the development of novel drug classes, including biologics (e.g., IL-33, IL-13/IL-4, and IL-5 inhibitors) and novel inhaled and nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue or halt disease progression.
QUESTIONS ANSWERED
Will LABA/LAMA FDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICS FDCs threaten these agents?
What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Advair, Trelegy, Breo; GSK / Innoviva’s Anoro; BI’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri, Symbicort)? What factors drive physicians’ treatment decisions?
How will the market evolve over the next 10-year forecast period?
Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-5 inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
What is the unmet need for COPD?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Advantages and Disadvantages of Short-Acting Bronchodilators
Expert Insight: Short-Acting Bronchodilators
Advantages and Disadvantages of Methylxanthines
Expert Insight: Methylxanthines
Medical Practice
Overview
Factors Influencing Drug Selection in COPD
Inhaler Devices for COPD
Treatment Decision Tree for COPD: United States
Treatment Decision Tree for COPD: Europe
Treatment Decision Tree for COPD: Japan
Unmet Need Overview
Current and Future Attainment of Unmet Needs in Chronic Obstructive Pulmonary Disease
Top Unmet Needs in Chronic Obstructive Pulmonary Disease: Current Attainment and Future Attainment
Expert Insight: Unmet Needs in Chronic Obstructive Pulmonary Disease
Emerging Therapies
Key Findings
Key Emerging Therapies
Key Therapies in Development for COPD
Estimated Launch Dates of Key Emerging Therapies for the Treatment of COPD
Dupilumab Profile
Analysis of the Clinical Development Program for Dupilumab
Expert Insight: Dupilumab
Expectations for Launch and Sales Opportunity of Dupilumab in COPD
Benralizumab Profile
Analysis of the Clinical Development Program for Benralizumab
Expert Insight: Benralizumab
Expectations for Launch and Sales Opportunity of Benralizumab in COPD
Mepolizumab Profile
Analysis of the Clinical Development Program for Mepolizumab
Expert Insight: Mepolizumab
Expectations for Launch and Sales Opportunity of Mepolizumab in COPD
Ensifentrine Profile
Analysis of the Clinical Development Program for Ensifentrine
Expert Insight: Ensifentrine
Expectations for Launch and Sales Opportunity of Ensifentrine in COPD
Itepekimab Profile
Analysis of the Clinical Development Program for Itepekimab
Expert Insight: Itepekimab
Expectations for Launch and Sales Opportunity of Itepekimab in COPD
Early-Phase Pipeline Analysis
Select Compounds in Early-Phase Development for COPD
Access & Reimbursement Overview
Region-Specific Reimbursement Practices
Key Market Access Considerations in COPD: United States
General Reimbursement Environment: United States
Key Market Access Considerations in COPD: EU5
General Reimbursement Environment: EU5
Key Market Access Considerations in COPD: Japan
General Reimbursement Environment: Japan
Appendix
COPD Bibliography
Anupama Ashish Joshi
Anupama Joshi, M.S. (Pharm.), is an associate analyst on the Immune and Inflammatory Disorders team at Clarivate. She focuses on respiratory diseases, particularly chronic obstructive pulmonary disease. Prior to joining Clarivate, Ms. Joshi was a research scientist in Dr. Reddy’s Laboratories. She obtained her master’s degree in pharmaceutical analysis from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), India.
Navya Vardhan
Navya Vardhan, M.Sc., is an associate epidemiologist at Clarivate. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.